Box SEQ 1646

Attorney Docket No. E1067/20019

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicants

Daniel Joseph O'Mahony

MAR 1 5 2001

Filed

November 19, 1999

...... _ 0 200,

Serial No.

09/443,986

TECH CENTER 1600/

For

RETRO-INVERSION PEPTIDES THAT TARGET

GIT RECEPTORS AND RELATED METHODS

Group Art Unit

1646

Examiner

J. Andres

Customer No.

0300

MAR 1 9 2001
TECH CENTER 1600/2900

REPLY REGARDING SEQUENCE LISTING

Commissioner of Patents Washington, DC 20231

Sir:

This submission is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated February 9, 2001 for the above patent application.

In support of the foregoing, please find the following:

- 1. Computer Disk containing Sequence Listing
- 2. Paper copy of Sequence Listing
- 3. Verified Statement regarding Sequence Listing (see p. 2 of this document)
- 4. Copy of Notice to Comply with Requirements for Patent Applications

 Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures

In accordance with the requirement of Box 7 of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures regarding the submission of sequence information incorporated by reference on page 3, lines 7-10 of the above patent application, pursuant to 37 C.F.R. 1.821(e), reference may be made to another application of the applicant on file in the Patent and Trademark Office (PTO) and computer readable form in lieu of filing a duplicate computer readable form in the new application if the computer readable form in the other application was compliant with all of the requirements of the sequence listing rules. It is the understanding of the undersigned that a computer readable form of the sequences listed in International Application No. PCT/US98/10088 (WO 98/51325), incorporated by reference in the present application which lists Daniel J. O'Mahony as an applicant, the same inventor here, is already on file with the PTO. Thus, applicant submits that a duplicate computer readable form is not required in this application.

If the entry of any of the foregoing requires a fee, or if an extension of time is required, then the PTO is authorized to charge the fee to deposit account 03-0075. A duplicate copy of this paper is enclosed.

VERIFIED STATEMENT REGARDING SEQUENCE LISTING

I hereby verify under 37 CFR § 1.821(f) that the paper copy and computer readable copy of the sequence listings of the sequences submitted herewith are the same and that no new matter is introduced.

CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.

March 9, 2001

Marilou E. Watson
Registration No. 42,213
Seven Penn Center
12th Floor
1635 Market Street
Philadelphia, PA 19103-2212
(215) 567-2010
Attorneys for Applicant

CERTIFICATE OF MAILING

I hereby certify that the foregoing Reply in duplicate, Computer Disk containing Sequence Listing, Paper copy of Sequence Listing, Verified Statement regarding Sequence Listing, Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, re Application Serial No. 09/443,986 are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents, Washington, DC 20231 on this 9th day of March, 2001.

Marilou E. Watson

Application No.: 09/443,986 NOTICE TO COMPLY WITH EQUIREMENTS FOR PATENT AND ICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for

the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.



- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as Indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The Application makes reference to specific protein and fragments and amino acid sequences (See Page 3, lines 7-10: 19. Table 1: 21. Table 3: Claims 1-17: and thus must comply with the sequence rules.

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An Initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE